If you have hepatitis C, your doctor may prescribe an antiviral medication, such as Mavyret (glecaprevir and pibrentasvir) or Epclusa (velpatasvir and sofosbuvir). Hepatitis C is a disease caused by the hepatitis C virus (HCV).

Mavyret and Epclusa are both combination prescription drugs used to help cure hepatitis C.

Although Mavyret and Epclusa are similar, they have differences, too. Keep reading to learn how these drugs compare.

Note: For more information about these drugs, see the in-depth articles on Mavyret and Epclusa.

Mavyret and Epclusa are both in the class of drugs called antivirals. (Classes are drugs grouped together by how they work.)

They’re also both combination medications:

  • Mavyret contains the active drugs glecaprevir and pibrentasvir.
  • Epclusa contains the active drugs velpatasvir and sofosbuvir.

Mavyret and Epclusa are both prescribed to treat chronic hepatitis C in adults and in some children. “Chronic” means long term. (For information on the use of these drugs in children, see the “Mavyret and children” and “Epclusa and children” sections below.)

For this use, hepatitis C must be caused by specific genotypes of the hepatitis C virus (HCV). Each hepatitis C genotype has its own genetic makeup.

Mavyret and Epclusa are both used to treat hepatitis C caused by:

  • HCV genotypes 1 to 6 in adults who have mild cirrhosis (liver scarring) or no cirrhosis

Mavyret is also used to treat hepatitis C caused by:

  • HCV genotype 1 in adults whose condition has been treated, but not cured, with a different medication

Epclusa is also used with the drug ribavirin to treat hepatitis C caused by:

  • HCV genotypes 1 to 6 in adults who have severe cirrhosis

Mavyret and children

Mavyret is used in children who either weigh at least 99 pounds (45 kilograms) or are ages 12 years and older. This drug treats hepatitis C caused by:

  • HCV genotype 1 in children whose condition has been treated, but not cured, with a different medication

Epclusa and children

Epclusa is used in children who either weigh at least 37 pounds (17 kilograms) or are ages 6 years and older. This drug treats hepatitis C caused by:

  • HCV genotypes 1 to 6 in children who have mild cirrhosis or no cirrhosis
  • HCV genotypes 1 to 6 in children who have severe cirrhosis, when used with ribavirin

Whether you have health insurance or not, cost may be a factor when you’re considering these drugs. To see cost estimates for Mavyret and Epclusa based on where you live, visit GoodRx.com. But keep in mind that what you’ll pay for either drug will depend on your treatment plan, health insurance, and the pharmacy you use.

Mavyret and Epclusa are both brand-name drugs. Mavyret isn’t available in generic form. However, Epclusa is available in generic form in one of its strengths: 400 milligrams (mg) of sofosbuvir and 100 mg of velpatasvir. Generic drugs are exact copies of the brand-name product but usually cost less.

If you’d prefer to use a generic drug to treat hepatitis C, ask your doctor if the generic form of Epclusa, or a different generic hepatitis C treatment, is right for you.

Get answers to some frequently asked questions about Mavyret and Epclusa.

Do Mavyret or Epclusa interact with any other drugs?

Yes. Mavyret and Epclusa can interact with other drugs.

For example, both Mavyret and Epclusa interact with the following drugs:

  • digoxin (Lanoxin, Digitek) for heart failure
  • certain antiviral drugs for HIV, such as efavirenz (Sustiva)
  • statins for lowering cholesterol, such as atorvastatin (Lipitor) or rosuvastatin (Crestor)
  • certain seizure drugs, such as phenytoin (Dilantin) and carbamazepine (Tegretol)

Also, Mavyret interacts with the following drugs:

And Epclusa interacts with the following drugs:

Mavyret and Epclusa may interact with certain herbs or supplements, too. For example, you shouldn’t take either medication with the herb St. John’s wort.

These aren’t all of the interactions possible with these drugs. For more information, see these in-depth articles on Mavyret and Epclusa. You can also talk with your doctor and pharmacist. In fact, you should talk with them before you use either drug. Telling them about any medications, vitamins, and herbs you use can help prevent interactions.

Can I take Mavyret or Epclusa if I have HIV and hepatitis C?

Yes, it’s possible. If you have both HIV and hepatitis C, you may be able to take Mavyret or Epclusa to treat your hepatitis C. Having HIV doesn’t change how either drug works in your body to help cure hepatitis C.

HIV treatment guidelines from the Department of Health and Human Services recommend that people with HIV as well as hepatitis C be treated for both conditions. Hepatitis C treatment can improve your liver and your overall health.

If you have HIV and hepatitis C, talk with your doctor about whether Mavyret or Epclusa might be a treatment option.

What can happen if I miss a dose of Mavyret or Epclusa?

If you miss a dose of Mavyret or Epclusa, the level of drug in your blood may get too low. A low drug level may make Mavyret or Epclusa less effective at treating hepatitis C.

Missing doses of either drug increases the chance that your hepatitis C won’t be cured.

Try your best to take either drug every day at about the same time. You’ll want to do this for the length of time prescribed by your doctor. Here are some tips to help you remember your medication:

  • Ask a friend, co-worker, or loved one to remind you.
  • Set a daily reminder on your smartphone or computer.
  • Make a medication calendar and post it on your fridge or near your coffee maker.
  • Fill a weekly or monthly pill organizer and place it by your toothbrush or on your bedstand.

If Mavyret or Epclusa cures my hepatitis C, can I have hepatitis C again?

Yes, it’s possible to have hepatitis C again after your condition is cured as a result of Mavyret or Epclusa treatment. This can happen in a couple of ways: relapse or re-exposure to the hepatitis C virus (HCV).

For your hepatitis C to be cured, you must have a sustained virologic response. This means tests can no longer detect HCV in your body. In rare cases, you could have a relapse if HCV is still present in your body. With a relapse, HCV becomes detectable and could start causing symptoms of hepatitis C again.

After your hepatitis C has been cured, there is a chance of contracting HCV again by being re-exposed to the virus. Taking certain precautions can help you avoid having hepatitis C again.

Could having certain health issues result in my doctor prescribing one drug over the other?

Yes. Your doctor may prescribe one drug over the other based on your health history and other factors. These may include:

  • Past hepatitis C treatments. They may choose one drug over the other based on any hepatitis C treatments you’ve tried before.
  • Liver function. If you have liver disease, Epclusa may be a better treatment choice for you.
  • Severe scarring of your liver. Mavyret isn’t used for treating hepatitis C if you have severe cirrhosis. However, Epclusa can be used with the drug ribavirin for this purpose.

Mavyret and Epclusa both come as tablets that you swallow whole. You shouldn’t crush, split, or chew Mavyret tablets. Doing so may make Mavyret less effective. It’s unknown if breaking up Epclusa tablets to take is safe.

If you can’t swallow Mavyret or Epclusa tablets whole, talk with your doctor about an alternative treatment for hepatitis C.

To treat hepatitis C with Mavyret, you take three tablets together with food once each day. You do this for 8 to 16 weeks, depending on your condition and past treatments. This dosage is the same for both adults and children.

The dosage for Epclusa depends on whether you’re an adult or child. Adults take one Epclusa tablet with or without food once each day for 12 weeks. For children’s dosage, see “Epclusa dosage in children” below.

When Epclusa is prescribed with the drug ribavirin, the Epclusa dosage is typically the same as when the drug is taken alone.

Epclusa dosage for children

The dose of Epclusa for children varies based on their weight. They take the dose their doctor prescribes once each day, with or without food, for 12 weeks. This is regardless of whether they take Epclusa alone or with ribavirin.

Most people who’ve taken Mavyret or Epclusa have had mild side effects. These are usually manageable and tend to go away with time.

But in rare cases, people have had serious side effects with both drugs. Some serious side effects, such as hepatitis B reactivation, could happen after you’ve finished Mavyret or Epclusa treatment. (See the “What are the warnings of Mavyret and Epclusa?” section below.)

Keep reading to learn about both mild and serious side effects with these drugs.

For more information about the possible side effects of each drug, see the side effects articles for Mavyret and Epclusa.

Mild side effects

Mavyret and Epclusa may cause mild side effects in some people. The chart below lists examples of mild side effects that have been reported with these drugs.

MavyretEpclusa
HeadacheXX
Fatigue (lack of energy)*XX
NauseaXX
High levels of bilirubin* (a byproduct of red blood cells being broken down), which may indicate liver problemsX
DiarrheaXX†
Insomnia (trouble sleeping)X
WeaknessX
Anemia (low red blood cell levels)X†

* This mild side effect may be a symptom of hepatitis C itself or of a serious side effect, such as reactivation of the hepatitis B virus (HBV). (See the “What are the warnings of Mavyret and Epclusa?” section below.)
† This mild side effect occurred in studies of people taking Epclusa with the drug ribavirin.

This chart may not include all mild side effects of these drugs. For more information on mild side effects of the two drugs, see Mavyret’s patient information and Epclusa’s prescribing information.

Serious side effects

In addition to the mild side effects described above, serious side effects may occur in people using Mavyret or Epclusa. See the chart below for a list of possible side effects.

MavyretEpclusa
Hepatitis B reactivation* (if you’ve had this virus before)XX
Serious allergic reactionXX

* Both Mavyret and Epclusa have a boxed warning for hepatitis B reactivation. This is the most serious warning from the Food and Drug Administration (FDA). To learn more, see the “What are the warnings of Mavyret and Epclusa?” section below.

Talk with your doctor about your medical history and risks for serious side effects with these drugs.

You may wonder how effective Mavyret and Epclusa are at treating hepatitis C. In studies of Mavyret and of Epclusa, both were highly effective at curing chronic hepatitis C caused by certain genotypes of the hepatitis C virus (HCV). Each hepatitis C genotype has its own genetic makeup.

According to the latest treatment guidelines from American Association for the Study of Liver Diseases, both drugs can be first-choice treatments for hepatitis C in people who:

  • have HCV that’s genotype 1 to 6
  • don’t have cirrhosis (liver scarring), or have mild cirrhosis, and
  • haven’t been treated for hepatitis C in the past

If you’d like to read more about how each drug performed in studies, see the prescribing information for Mavyret and Epclusa.

Mavyret and Epclusa may not be right for you if you have certain medical conditions or other factors that affect your health. Here, these are referred to as warnings. The two drugs share some of the same warnings, but they also have different ones. Some of these warnings are mentioned below.

Before you start using Mavyret or Epclusa, be sure to talk with your doctor to see if these warnings apply to you.

Boxed warning: Hepatitis B reactivation

Mavyret and Epclusa have a boxed warning. This is the most serious warning from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

Hepatitis B reactivation. If you’ve had hepatitis B in the past, using Mavyret or Epclusa could make the hepatitis B virus (HBV) reactivate in your body. This means hepatitis B could flare up again. In rare cases, flare-ups can cause serious or fatal liver failure.

Before you start to take either drug, tell your doctor if you’ve had hepatitis B. They may test you for HBV prior to taking Mavyret or Epclusa. If you have HBV, you may need hepatitis B treatment before starting Mavyret or Epclusa. Your doctor may also watch you closely during and after treatment with either drug.

Other warnings

In addition to boxed warnings, Mavyret and Epclusa have other warnings.

Before using Mavyret or Epclusa, talk with your doctor if any of the following conditions or health factors apply to you.

  • Warnings for Mavyret:
    • if you take the HIV drugs atazanavir (Reyataz) or efavirenz (Sustiva)
  • Warnings for Epclusa:
    • if you take the heart arrythmia drug amiodarone (Pacerone, Nexterone)
    • if you can’t take the antiviral drug ribavirin, but would require combination treatment of Epclusa and ribavirin to treat hepatitis C in certain situations
  • Warnings for both Mavyret and Epclusa:
    • if you’re pregnant or breastfeeding, or planning to become pregnant or breastfeed
    • if you take the herb St. John’s wort
    • if you take the antibiotic drug rifampin (Rifadin)
    • if you’ve received a liver transplant
    • if you have HIV

To learn more about these drugs, see the in-depth articles on Mavyret and Epclusa.

The short answer: Probably not.

Details: Mavyret and Epclusa treatment involve short-term regimens. They need to be taken every day to help cure hepatitis C. Although they work in similar ways and are used for similar types of hepatitis C, they aren’t exactly the same. For example, they aren’t necessarily used for the same length of time.

Unless you have a serious side effect with either drug, you’ll need to stay on the exact regimen as prescribed by your doctor. This means taking the same drug for the amount of time they recommend and not skipping doses. Doing this will increase the likelihood that your hepatitis C will be cured.

At the end of your treatment period, your doctor will test you for the hepatitis C virus (HCV). If the test can still detect HCV in your body, they’ll prescribe a new hepatitis C treatment.

If Epclusa didn’t cure your hepatitis C, your doctor may prescribe Mavyret. But this depends on many factors, such as your condition, type of hepatitis C, and past treatment.

If Mavyret didn’t cure the hepatitis C condition, Epclusa isn’t a second treatment option. In this case, other treatments are better options.

Reminder: To increase the chance of hepatitis C being cured, you need to take Mavyret or Epclusa exactly as prescribed. Don’t miss doses, switch drugs, or stop your current treatment unless your doctor recommends it.

Taking Mavyret or Epclusa may cure your hepatitis C. When taken exactly as prescribed, both drugs are highly effective at curing this disease.

Depending on your condition, you may only have to take Mavyret for 8 weeks compared with 12 weeks for Epclusa. However, your doctor may prescribe Epclusa if you have severe liver disease.

Talk with your doctor about the best choice for you. They can answer your questions so that you feel confident about your hepatitis C treatment. Ask about any concerns, such as:

  • Do I have any health factors that make Mavyret or Epclusa a better fit?
  • What should I do if I miss a dose of either Mavyret or Epclusa? Would I have to start treatment over?
  • Are there any financial resources that would make one treatment cheaper than the other?
  • If I’m a good candidate for both drugs, are there reasons why one would be prescribed over the other?
  • Does one of these drugs have a higher rate of relapse associated with it?

If you have hepatitis C and HIV, subscribe to our HIV newsletter for resources, personal stories, and more.

Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.